

REMARKS


By the foregoing amendments, a paper copy, as well as a computer readable form (CRF) copy, of the Sequence Listing for the sequence disclosure found at page 1, lines 27-28 of the present specification, has been added to the present application, pursuant to 37 C.F.R. §§ 1.821 to 1.825. In addition, page 1 of the present specification has been amended by the foregoing amendments to assign a SEQ ID NO to the aforesaid sequence disclosure. Applicants hereby represent that this submission and the foregoing amendments contain no new matter. Thus, it is respectfully submitted that this Amendment / Response to Notice to Comply constitutes a complete response to the communication, mailed August 27, 2001, including the Notice to Comply. A copy of the communication and the Notice to Comply are also attached hereto.

In addition, it is respectfully submitted that the sequence disclosure found at page 4, lines 29-30 of the present specification is exempt from the requirements of 37 C.F.R. §§ 1.821 to 1.825 because this sequence contains at least one D-amino acid (e.g., D-Arg or D-Cit). This position was confirmed by a telephone discussion with Dr. Low at (703) 308-2923. Thus, no sequence listing has been submitted herewith for the sequence disclosure found at page 4, lines 29-30 of the present specification.

No fees are believed to be due in connection with the submission of this Amendment/Response to Notice to Comply. However, if any such fees, including extension or petition fees, are due, the Examiner is hereby authorized to charge them to Deposit Account No. 19-1218.

Respectfully Submitted,

SELITTO, BEHR & KIM

By: 
Omri M. Behr
Reg. No. 22,940

SELITTO, BEHR & KIM
P.O. Box 1477
Edison, New Jersey 08818-1477
(732) 777-9050

VERSION WITH MARKINGS TO SHOW CHANGES

In the Specification

A paper copy of a sequence listing has been added.

Page 1, the fourth full paragraph (lines 20-28) has been amended as follows:

Release of GH is under the control of releasing and inhibiting factors secreted by the hypothalamus. The primary releasing factor is growth hormone releasing hormone ("GH-RH"); human growth hormone-releasing hormone ("hGH-RH") is a peptide having 44 amino acids. The novel peptides of the present invention relate to analogues of hGH-RH having only residues 1 through 29 ("hGH-RH(1-29)NH₂"), i.e., to analogues of the peptide which has the amino acid sequence:

Tyr-Ala-Asp-Ala-Ile⁵-Phe-Thr-Asn-Ser-Tyr¹⁰-Arg-Lys-Val-Leu-Gly¹⁵-

Gln-Leu-Ser-Ala-Arg²⁰-Lys-Leu-Leu-Gln-Asp²⁵-Ile-Met-Ser-Arg²⁹-NH₂

(SEQ ID NO: 1).